Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use

Research in Developmental Disabilities

Volumn 31, Issue 1, 2010, Pages 108-116

  Matson, Johnny L ^a   Fodstad, Jill C ^a   Neal, Daniene ^a   Dempsey, Timothy ^a   Rivet, Tessa T ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Adults; Intellectual disabilities; MEDS; Psychotropic medication; Side effects; Tardive dyskinesia

Indexed keywords

PSYCHOTROPIC AGENT;

ADULT; AGE; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG USE; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MATSON EVALUATION OF DRUG SIDE EFFECT; MENTAL DISEASE; PATIENT ASSESSMENT; RATING SCALE; RISK FACTOR; TARDIVE DYSKINESIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LONG-TERM CARE; MALE; MENTAL DISORDERS; MENTAL RETARDATION; MIDDLE AGED; NEUROLOGIC EXAMINATION; SEROTONIN UPTAKE INHIBITORS;

EID: 70350707623     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2009.08.002     Document Type: Article

References (50)

1. Advokat C.D., Mayville E.A., and Matson J.L. Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Research in Developmental Disabilities 21 (2000) 75-84
2. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. (2000), APA, Washington, DC [Text Revision]
3. Bamburg J.W., Cherry K.E., Matson J.L., and Penn D. Assessment of schizophrenia in persons with severe and profound mental retardation using the Diagnostic Assessment for the Severely Handicapped-II (DASH-II). Journal of Developmental and Physical Disabilities 13 (2001) 319-331
4. Brown K.W., and White T. The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenia patients. Biological Psychiatry 30 (1991) 1182-1190
5. Casey D.E. Tardive dyskinesia and affective disorders. In: Gardos G., and Casey D.E. (Eds). Tardive dyskinesia and affective disorders (1984), American Psychiatric Press, Washington, DC
6. Casey D.E., and Gerlach J. Tardive dyskinesia: What is the long-term outcome?. In: Casey D.E., and Gardos G. (Eds). Tardive dyskinesia and neuroleptics: From dogma to reason (1984), American Psychiatric Press, Washington, DC
7. Cherry K.E., Penn D., Matson J.L., and Bamburg J.W. Characteristics of schizophrenia among persons with severe or profound mental retardation. Psychiatric Services 51 (2000) 922-924
8. Dixon D.R., Kurtz P.F., and Chin M.D. A systematic review of challenging behaviors in children exposed to substances of abuse. Research in Developmental Disabilities 29 (2008) 483-502
9. Holden B., and Gitlesen J.P. The relationship between psychiatric symptomatology and motivation of challenging behavior: A preliminary study. Research in Developmental Disabilities 29 (2008) 408-413
10. Kane J.M. Tardive dyskinesia in affective disorders. Journal of Clinical Psychiatry 60 (1999) 43-47
11. Kane J.M., and Smith J.M. Tardive dyskinesia: Prevalence and risk factors, 1959-1979. Archives of General Psychiatry 39 (1982) 473-481
12. Koshino Y., Madokoro S., Ito T., Horie T., Mukai M., and Isaki K. A survey of tardive dyskinesia in psychiatric inpatients in Japan. Clinical Neuropharmacology 15 (1992) 34-43
13. Kurtz P.F., Chin M.D., Rush K.S., and Dixon D.R. Treatment of challenging behavior exhibited by children with prenatal drug exposure. Research in Developmental Disabilities 29 (2008) 582-594
14. Liddle P.F., Barnes T.R., Speller J., and Kibel D. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. British Journal of Psychiatry 163 (1993) 776-780
15. Lifshitz H., Merrick J., and Morad M. Health status and ADL functioning of older persons with intellectual disability: Community residence versus residential care centers. Research in Developmental Disabilities 29 (2008) 301-315
16. Jeste D.V., and Caligiuri M.P. Tardive dyskinesia. Schizophrenia Bulletin 19 (1993) 303-315
17. Matson J.L. Assessment of dual diagnosis (ADD) (1997), Disability Consultants, LLC, Baton Rouge, LA. http://disabilityconsultants.org
18. Matson J.L. Matson evaluation of drug side-effects (MEDS) (1998), Disability Consultants, LLC, Baton Rouge, LA. http://disabilityconsultants.org
19. Matson J.L., Bamburg J.W., Mayville E.A., and Logan J.R. Tardive dyskinesia nad developmental disabilities: An examination of demographics and topography in persons with dual diagnosis. British Journal of Developmental Disabilities 46 (2000) 119-130
20. Matson J.L., Cooper C., Malone C.J., and Moskow S.L. The relationship of self-injurious behavior and other maladaptive behaviors among individuals with severe and profound intellectual disability. Research in Developmental Disabilities 29 (2008) 141-148
21. Matson J.L., and Dempsey T. Autism spectrum disorders: Pharmacotherapy for challenging behaviors. Journal of Developmental and Physical Disabilities 20 (2008) 175-191
22. Matson J.L., Dempsey T., LoVullo S.V., and Wilkins J. The effects of functioning on the range of core symptoms of autism spectrum disorders. Research in Developmental Disabilities 29 (2008) 341-350
23. Matson J.L., Fodstad J.C., and Rivet T.T. The convergent and divergent validity of the Matson Evaluation of Drug Side-effects and the Dyskinesia Identification System Condensed User Scale (DISCUS). Journal of Intellectual Developmental Disabilities 33 (2008) 337-344
24. Matson J.L., Hamilton M., Duncan D., Bamburg J., Smiroldo B.B., Anderson S., et al. Characteristics of stereotypic movement disorder and self-injurious behavior assessed with the Diagnostic Assessment for the Severely handicapped-II (DASH-II). Research in Developmental Disabilities 18 (1997) 457-469
25. Matson J.L., Kiely S.L., and Bamburg J.W. The effect of stereotypies on adaptive skills as assessed with the DASH-II and Vineland Adaptive Behavior Scales. Research in Developmental Disabilities 18 (1997) 471-476
26. Matson J.L., and LoVullo S.V. A review of behavioral treatments for self-injurious behaviors of persons with autism spectrum disorders. Behavior Modification 32 (2008) 61-76
27. Matson J.L., Mayville E.A., Bamburg J.W., and Eckholdt C.S. An analysis of side- effect profiles of anti-seizure medications in persons with intellectual disability using the Matson Evaluation of Drug Side Effects (MEDS). Journal of Intellectual and Developmental Disability 26 (2001) 283-295
28. Matson J.L., Mayville E.A., Bielecki J., Barnes W.H., Bamburg J.W., and Baglio C.S. Reliability of the matson evaluation of drug side effects (MEDS). Research in Developmental Disabilities 19 (1998) 501-506
29. Matson J.L., and Minshawi N.F. Functional assessment of challenging behaviors: Toward a strategy for applied settings. Research in Developmental Disabilities 28 (2007) 353-361
30. Matson J.L., and Rivet T.T. Characteristics of challenging behaviours in adults with autistic disorder, PDD-NOS, and intellectual disability. Journal of Intellectual and Developmental Disabilitiy 33 (2008) 323-329
31. Matson J.L., Rivet T.T., and Fodstad J.C. Psychometric properties and participant characteristics for persons with intellectual disability using the Matson Evaluation of Drug Side-effects (MEDS). Journal of Developmental and Physical Disabilities 20 (2008) 243-255
32. Matson J.L., Rivet T.T., and Fodstad J.C. Matson evaluation of drug side-effects (MEDS) profiles in adults with intellectual disability, tardive dyskinesia, and akathesia. Journal of Developmental and Physical Disabilities 20 (2008) 283-295
33. Matson J.L., Rivet T.T., and Fodstad J.C. Matson evaluation of drug side-effects (MEDS) profiles of selective serotonin reuptake inhibitors (SSRI) in adults with intellectual disability. Journal of Developmental and Physical Disabilities 21 (2009) 57-68
34. Matson J.L., Rush K.S., Hamilton M., Anderson S.J., Bamburg J.W., Baglio C.S., et al. Characteristics of depression as assessed by the Diagnostic Assessment for the Severely Handicapped-II (DASH-II). Research in Developmental Disabilities 20 (1999) 305-313
35. Matson J.L., and Smiroldo B.B. Validity of the mania subscale of the Diagnostic Assessment for the Severely Handicapped-II (DASH-II). Research in developmental Disabilities 18 (1997) 221-225
36. Matson J.L., Smiroldo B.B., Hamilton M., and Baglio C.S. Do anxiety disorders exist in persons with severe and profound mental retardation?. Research in Developmental Disabilities 18 (1997) 39-44
37. Matson J.L., and Wilkins J. Antipsychotic drugs for aggression in intellectual disability. The Lancet 371 (2008) 9-10
38. McGillibray J.A., McCabe M.P., and Kershaw M.M. Depression in people with intellectual disability: An evaluation of a staff-administered treatment program. Research in Developmental Disabilities 29 (2008) 524-536
39. Myrbakk E., and von Tetzchner S. Psychiatric disorders and behavior problems in people with intellectual disability. Research in Developmental Disabilities 29 (2008) 316-332
40. Paclawskyj T.R., Matson J.L., Bamburg J.W., and Baglio C.S. A comparison of the diagnostic for the severely handicapped-II (DASH-II) and the aberrant behavior checklist (ABC). Research in Developmental Disabilities 18 (1997) 289-298
41. Paclawskyj T.R., Matson J.L., Rush K.S., Smalls Y., and Vollmer T.R. Questions about behavioral function (QABF): A behavioral checklist for functional assessment of aberrant behavior. Research in Developmental Disabilites 21 (2000) 223-229
42. Ricjken C.A.W., Monster T.B.M., Brouwers J.R.B.J., and de Jong-van den Berg L.T.W. Chlorpromazine equivalents versus defined daily doses: How to compare antipsychotic drug doses?. Journal of Clinical Psychopharmacology 23 (2003) 657-659
43. Ringdahl J.E., Call N.A., Mews J.B., Boelter E.W., and Christensen T.J. Assessment and treatment of aggressive behavior without a clear social function. Research in Developmental Disabilities 29 (2008) 351-362
44. Romero R., Knapp M., Tyrer P., Crawford M., and Oliver-Africano P. The treatment of challenging behavior in intellectual disabilities: Cost-effective analysis. Journal of Intellectual Disability Research 53 (2009) 633-643
45. Sandyk R., Kay S.R., Awerbuch G.I., and Iacono R.P. Risk factors for neuroleptic-induced movement disorders. International Journal of Neuroscience 61 (1991) 149-188
46. Sparrow S., Balla D., and Cicchetti D.V. The Vineland Adaptive Behavior Scales (Survey Form) (1984), American Guidance Service, Circle Pines, MN
47. Tabachnick B.G., and Fidell L.S. Using multivariate statistics. 5th ed. (2007), Pearson Education, Inc., Boston, MA
48. Tyrer P., Oliver-Africano P.C., Ahmed Z., Bouras N., Cooray S., Deb S., et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behavior in patients with intellectual disability: A randomized controlled trial. The Lancet 371 (2008) 57-63
49. Van Os J., Fahy T., Jones P., Harvey I., Toone B., and Murray R. Tardive dyskinesia: Who is at risk?. Acta Psychiatrica Scandinnavica 96 (1997) 206-216
50. World Health Organization (WHO). Collaborating centre for drug statistics methodology. ATC/DDD Index 2007. http://www.whocc.no/atcddd/. Retrieved October 2007.